Thomas B Cueni, Director General, International Federation of Pharmaceutical Manufacturers and Associations tells NDTV that "economies are starting to come out of the pandemic and price in rich countries is pretty similar to what one pays for the seasonal flu vaccine, but when you look at the importance of COVID-19 vaccines, it is truly important and high value and pretty much all the companies do charge low prices to middle income and low-income countries."